PfSPZ Malaria Vaccine
Journal: International Journal of Science and Research (IJSR) (Vol.11, No. 3)Publication Date: 2022-03-05
Authors : Dwi Ayu Fani Novitasari;
Page : 76-77
Keywords : vaccine; malaria; PfSPZ;
Abstract
Malaria is a disease caused by parasites. As we know that parasites have 3 life cycles while it?s on the human host: pre-erythrocytes phase, blood-stage phase, and transmission-blocking phase. As for now, the medicine for malaria disease is artemisin combination therapy which is going to be resistant, so people try to develop a vaccine for malaria to meet the goal of malaria eradication. One of the vaccines developed is RTS,S/AS01. RTS,S/AS01 is pre-erythrocytic vaccine that confers efficacy against controlled human malaria infection in about 22% in healthy malaria 5 months after vaccination. In clinical trial phase 3, RTS,S/AS01 was 26% in young infants and 36% in children (Ishizuka et al., 2016). Eradication of malaria needs vaccine protection of more than 80% and has protective efficacy for more than 6 months. Therefore, the development of a malaria vaccine is still needed. Another malaria vaccine is PfSPZ. PfSPZ is pre-erythrocytic stage vaccine similar to RTS,S/AS01. It is whole attenuated sporozoite Plasmodium falciparum.
Other Latest Articles
- Journey of Chandrayaan Missions
- A Review of Morphology, Bioactive Compounds and Anti-Bacterial Activities of Solvents and its Extracts of the Plant Phyllanthus emblica, the Indigeneous Medicinal Plant of the Sikkim Himalayas
- Impact of Environmental Conditions on Release of Iron to Overlying Water from Selective Fertilized Soil of Udaipur District, Rajasthan
- Development Strategy of Steam Educational Books Subject Selection Based on SECI Model
- Assessment of Facilties and Operations in Cattle Abbatoirs in Kampala, Uganda
Last modified: 2022-05-14 21:02:36